Quantcast
Last updated on April 24, 2014 at 5:50 EDT

Latest Regenesis Biomedical Inc. Stories

2013-12-18 16:24:18

Clinicians can now treat the post-operative pain from joint replacements and spinal fusions SCOTTSDALE, Ariz., Dec. 18, 2013 /PRNewswire/ -- Regenesis Biomedical, Inc., today announced that FDA has approved the removal of the contraindication for use of the Company's Provant Therapy System in patients with metallic implants in the area of treatment. The decision was made after the FDA reviewed additional data and research demonstrating that the use of Provant's Pulsed...

2013-05-13 20:22:33

Recognized compassionate pioneer loses her battle with pancreatic cancer SCOTTSDALE, Ariz., May 13, 2013 /PRNewswire/ -- Regenesis Biomedical, Inc., a medical technology company focused on tissue regeneration, announced today that CEO Virginia Rybski lost her battle with pancreatic cancer. Virginia was compassionately dedicated to her family, colleagues, patients and faith. (Photo: http://photos.prnewswire.com/prnh/20130513/LA13153) (Logo:...

2012-01-16 09:57:00

SCOTTSDALE, Ariz., Jan. 16, 2012 /PRNewswire/ -- Regenesis Biomedical, Inc., a medical technology company that markets the Provant® Therapy System, announced today that Scott Brooks has joined the company in the newly created position of Chief Operating Officer. Scott is responsible for helping scale the organization's capabilities to support increased market penetration and broadened reimbursement. (Logo: http://photos.prnewswire.com/prnh/20120109/LA31405LOGO) Most recently...

2012-01-09 06:00:00

SCOTTSDALE, Ariz., Jan. 9, 2012 /PRNewswire/ -- Regenesis Biomedical, Inc., a medical technology company that markets the Provant® Therapy System, announced today William (Bill) Gittinger joined the company as Vice President of Reimbursement and Health Economics. In this new role, Bill is chartered with securing expanded payor sources for the Provant Therapy System. Primary emphasis is on Medicare, Medicaid and commercial payors. He is also responsible for demonstrating the...

2011-06-06 07:00:00

SCOTTSDALE, Ariz., June 6, 2011 /PRNewswire/ -- Regenesis Biomedical, Inc., a medical technology company that markets the Provant® Therapy System, announced today the closing of a $5.3 million Series C equity financing. The financing was led by Fulcrum Equity Partners and TGap Ventures, and includes existing investor Solstice Capital. Tom Greer of Fulcrum and Jack Ahrens of TGap will join the Regenesis Board of Directors. "During our investment due diligence, we were...

2010-03-02 10:38:00

SCOTTSDALE, Ariz., March 2 /PRNewswire/ -- Regenesis Biomedical, Inc., a medical technology company focused on regenerative medicine, announced today that Peter Sheehan, MD, has joined the company's Board of Directors and will serve as Chairman of their Medical Advisory Board. Dr. Sheehan is an internationally respected specialist in the field of diabetes. Areas of clinical and research interest for Dr. Sheehan include peripheral artery disease, diabetic neuropathy, and wound healing. He...

2008-08-22 12:00:52

SCOTTSDALE, Ariz., Aug. 22 /PRNewswire/ -- Regenesis Biomedical, Inc., a medical technology company that markets the Provant(R) Wound Therapy System, announced today the addition of two members to its Board of Directors. The two new directors are Peter G. Savas, Chairman and CEO of Alseres Pharmaceuticals, and Charles "Chuck" S. Lunden, a principal with Bederson and Company. (Logo: http://www.newscom.com/cgi-bin/prnh/20080422/LATU008) Peter Savas serves as Chairman and Chief Executive...

2008-06-17 12:00:57

SCOTTSDALE, Ariz., June 17 /PRNewswire/ -- Regenesis Biomedical, Inc., a medical technology company that markets the Provant(R) Wound Therapy System, announced today their accreditation as an Exemplary Provider for Medicare beneficiaries. The Medicare Modernization Act requires that all DMEPOS (Durable Medical Equipment, Prosthetics, Orthotics, Supplies) providers who participate in the Medicare program must be successfully accredited. (Logo:...